Your session is about to expire
← Back to Search
Pioglitazone 30 Mg Oral Tablet for Prostate Cancer
Study Summary
This trial will study the mechanisms of how a hormone-blocking therapy for prostate cancer can cause insulin resistance and evaluate a treatment to decrease that insulin resistance.
- Prostate Cancer
- Insulin Resistance
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there opportunities for new participants to join the clinical trial at this time?
"According to the information maintained on clinicaltrials.gov, this medical trial is accepting applicants at present. It was first posted in December 1st 2022 and its parameters were last adjusted November 11th 2022."
Am I suitable to partake in this clinical experiment?
"This trial is inviting 44 individuals with insulin resistance, ranging in age from 18 to 85 years old. Specifically, this study seeks male participants within the same age range."
Has there been prior research concerning the effectiveness of Pioglitazone 30 Mg Oral Tablet?
"Currently, 31 studies are exploring the use of Pioglitazone 30 Mg Oral Tablets with 4 trials in their third phase. These research initiatives span 69 destinations across the globe, some within Lausanne, Vaud specifically."
What is the total enrollment of participants in this clinical trial?
"Affirmative. The clinicaltrials.gov website indicates that this study, initially published on December 1st 2022, is currently recruiting volunteers. 44 participants are needed across one medical centre."
Are elderly individuals of eighty-five years or younger eligible for this trial?
"The requirements for this research include being between 18 and 85 years old. There are 102 studies available to those below the age of consent, while 1428 studies have been conducted with people aged over 65."
What medical conditions has Pioglitazone 30 Mg Oral Tablet been found to be efficacious in treating?
"Pioglitazone 30 Mg Oral Tablet is a feasible treatment option for diabetes, diabetic neuralgia, and dietary problems."
Share this study with friends
Copy Link
Messenger